Vis børsmeldingen
14,000 by issuance of 140,000 new shares. The new shares are subscribed for by
an option owner that wishes and is entitled to exercise options in accordance
with the Company’s option scheme. The subscription price is in accordance with
the prevailing options price pursuant to the CompanyŽs option scheme, NOK 10.62
per share.
The capital increase is expected to be registered within 7 days, and following
the issuance of the new shares, the issued share capital of BerGenBio ASA will
be NOK 5,485,144.60 consisting of 54,851,446 shares, each with a par value of
NOK 0.10.
-End-
Contacts
Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304
Rune Skeie
CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
http://www.netfonds.no/quotes/release.php?id=20190214.OBI.20190214S177